World Health Organization (WHO) · Technical Documents

Polio Bulletin - 2015, Issue no. 06 (Week 13)

March 31, 2015 World Health Organization

The full text is hosted by the publishing organisation. lawenc.com indexes the metadata and links to the official source.

Full text

2015 Issue No. 6 - Week 13 (as of 31 March 2015) HIGHLIGHTS Type 2 Certification of Eradication The Global Commission for the Certification of polio eradication (GCC), at its next meeting during the second half of 2015, will consider evidence to declare that wild poliovirus type 2 (WPV2) was eradicated globally more than 10 years ago. All Members States in the Western Pacific Region are requested to provide no later than end-April 2015 a formal statement to the Regional Certification Commission through WHO confirming when WPV2 was last detected in the country (if ever). The information received from countries will be critically important for the GCC’s decision/ declaration on WPV2. Information in WHO about when WPV2 was last detected in Members States of the Western Pacific Region is as follows: 3.0

Polio Bulletin

Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age), 2013–2015* 100%

Chart 2. Adequate specimen collection rate, 2013–2015

2.5

80%

2.0 60%

1.5 40%

1.0 20%

0.5

0.0 13 14 CHN 15 13 14 KHM 15 13 14 LAO 15 13 14 MYS 15 13 14 PHL 15 13 14 PNG 15 13 14 VNM 15

0% 13 14 CHN 15 13 14 KHM 15 13 14 LAO 15 13 14 MYS 15 13 14 PHL 15 13 14 PNG 15 13 14 VNM 15

* AFP rate annualized as of week 13

 Australia - 1965  Cambodia - 1989  China - before 1985  Japan - 1970  Singapore - 1971  Viet Nam - 1989 No information is available about the detection of WPV2 for other Member States. 80% 100%

Chart 3. Percentage of reported AFP cases by number of polio vaccination doses, 2015

Chart 4. Percentage of reported AFP cases with pending classification > 90 days after onset, 2015 CHN KHM LAO MYS

60%

40%

PHL PNG VNM

CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization

20%

0% CHN KHM LAO MYS 1-2 doses

PHL 0 doses

PNG Unknown

VNM

20%

40%

60%

80%

100%

≥ 3 doses

Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2014 and key surveillance indicators 2013 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with % with investigated 60-day adequate 2 days of ≤ 4 specimens 2 3 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date 5 Days since last report 6

2014 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries and areas Total 1. 2. 3. 4. 5. 6.

62 1 73 5623 12 1 0 48 155 7 12 18 277 84 7 459 8 6847

44 1 46 2225 8 1 167 25 77 8 9 30 378 72 6 231 10 3338

61 4 72 5774 19 1 0 28 161 9 8 12 277 88 8 358 15 6895

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

57 2 68 5562 19 1 27 161 9 8 11 236 88 8 293 10 6560

4 2 4 212 0 0 1 0 0 0 1 40 0 0 65 5 334

3 (4.9%) 0 (0.0%) 1 (1.4%) 183 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 34 (12.3%) 0 (0.0%) 0 (0.0%) 61 (17.0%) 5 (33.3%) 287 (4.2%) Green Yellow Red

1.39 4.00 1.57 2.60 2.38 1.00 1.12 2.09 1.13 0.89 0.40 0.73 1.22 1.33 1.55 1.50 2.07

44% 75% 96% 92% 89% 0% 57% 73% 89% 38% 33% 59% 86% 75% 97% 67% 90%

84% 100% 93% 100% 100% 100% 93% 87% 100% 100% 75% 97% 98% 88% 93% 93% 99%

0% 100% 67% 95% 100% 100% 83% 100% 100% 80% 0% 6% 100% 100% 100% 80% 75%

20-Feb-15 07-Feb-15 16-Feb-15 25-Mar-15 05-Mar-15 13-Jan-15 04-Feb-15 10-Mar-15 05-Mar-15 11-Mar-15 04-Mar-15 12-Mar-15 16-Feb-15 07-Jan-15 18-Mar-15 23-Mar-15

39 52 43 6 55 27 19 13 8

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens for which the 60-day follow-up evaluation has been completed Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 1B. Classification of AFP cases with onset in 2015 and key surveillance indicators 2014 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with % with investigated adequate 60-day 2 days of ≤ 5 specimens 3 4 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date Days since last report 6

2015 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

61 4 72 5774 19 1 0 28 161 9 8 12 277 88 8 358 15 6895

44 1 46 2234 8 1 163 26 77 9 9 34 387 70 6 231 10 3356

2 0 4 639 2 0 0 5 22 1 1 2 47 12 2 0 0 739

0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 78 1 3 1 0 0 0 0 7 2 92

2 4 561 1 2 21 1 1 2 47 5 0 647

0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Green Yellow Red

0.18 0.35 1.14 1.00 0.77 1.14 0.44 0.44 0.24 0.49 0.69 1.33 0.88

0% 100% 93% 100% 80% 86% 100% 100% 100% 51% 67% 100% 90%

100% 100% 100% 100% 100% 50% 100% 100% 50% 98% 100% 100% 98%

0% 35% 0% 33% 0% 25% 22%

20-Feb-15 05-Feb-15 09-Feb-15 25-Mar-15 05-Mar-15 12-Mar-15 30-Mar-15 10-Mar-15 05-Mar-15 11-Mar-15 02-Mar-15 12-Mar-15 18-Mar-15 02-Mar-15 09-Feb-15 24-Mar-15

39 54 50 6 26 19 1 21 26 20 29 19 13 29 50 7

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens for which the 60-day follow-up evaluation has been completed Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 2A. Laboratory investigation of AFP cases with onset in 2014 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with positive specimens L20B positive + NPEV NPEV only Pending Negative ≤ 14 days % % results Latest Pending reported specimens report date positive > 14 2 ≤ 14 days for NPEV days ≥ 80% Intratypic differentiation/ 1 Sequencing lab No. of isolates received Type 1 W ild Sabin VDPV Wild Intratypic differentiation (ITD)/sequencing results Type 2 Sabin VDPV W ild Type 3 Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 pending days of sequencing receipt ≥ 80%

Australia Brunei Darussalam Cambodia China China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam (North) Viet Nam (South) Pacific island countries and areas Total

VIDRL VIDRL NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC NIID NIID IMR PHI IESR VIDRL RITM NIH SGH NIHE PI VIDRL

45 2 73 5706 334 40 213 121 354 278 332 150 536 267 319 190 54 103 397 29 206 412 27 103 267 189 73 204 43 186 137 87 31 21 3 19 0 0 25 164 9 5 10 342 88 8 216 136 12 6860

0 0 5 111 20 1 2 0 4 6 11 2 4 4 18 2 1 1 5 2 4 4 0 1 11 2 0 0 0 2 1 1 2 0 0 0 1 0 0 0 0 5 0 0 0 0 0 122

0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 3

2 0 12 580 26 0 27 8 47 56 37 7 61 36 3 27 7 4 39 0 2 42 3 5 38 20 14 23 7 23 11 3 0 4 0 4 5 4 1 1 4 13 8 0 30 16 1 681

43 2 56 4995 287 39 184 113 303 214 283 141 470 222 298 161 46 97 352 27 200 364 24 94 218 167 59 181 36 161 123 82 29 17 3 15 19 160 8 4 5 324 80 8 186 120 11 6036

0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1

0 0 0 18 1 0 0 0 0 2 0 0 1 5 0 0 0 1 0 0 0 2 0 3 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 18

96% 50% 96% 75% 83% 81% 92% 79% 81% 64% 69% 89% 80% 90% 79% 92% 66% 87% 83% 98% 56% 42% 93% 96% 51% 69% 71% 91% 76% 60% 85% 65% 76% 93% 75% 93% 100% 100% 100% 91% 100% 88% 97% 100% 100% 93% 100% 76%

2% 0% 14% 8% 7% 0% 10% 5% 11% 16% 8% 4% 9% 13% 1% 13% 11% 4% 7% 0% 1% 9% 9% 4% 11% 8% 15% 10% 14% 12% 7% 2% 0% 17% 0% 11% 18% 2% 11% 18% 50% 3% 10% 0% 12% 11% 4% 8%

22-Jan-15 22-Jan-15 02-Feb-15 25-Mar-15

VIDRL VIDRL NIID Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

0 0 10 307 45 11 3 6 9 12 11 6 6 4 44 4 4 2 8 6 12 10 10 6 24 8 4 13 0 6 19 8 6 0 0 0 0 0 0 0 0 0 4 13 2 0 0 0 0 336

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 72 10 3 0 2 4 0 2 0 1 2 7 1 1 0 3 0 2 4 2 4 7 0 0 0 4 9 4 0 0 4 0 76

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

10 106 14 1 0 2 3 7 6 2 2 2 15 0 1 2 3 2 6 4 4 2 7 2 2 7 0 4 2 4 0 6 0 122

0 4 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 5

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 113 21 7 3 2 2 5 1 3 3 0 17 1 2 0 2 4 2 2 4 0 10 4 2 6 2 4 2 2 2 2 0 117

0 2 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2

0 7 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 2 0 0 2 0 2 11

0 3 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 95% 91% 100% 100% 100% 78% 100% 100% 100% 75% 100% 97% 100% 100% 100% 100% 100% 90% 100% 100% 100% 93% 100% 100% 82% 100% 100% 100% 100% 100% 100% 100% 96%

13-Jan-15 13-Jan-15 22-Jan-15 10-Feb-15 16-Mar-15 12-Jan-15 22-Jan-15 11-Mar-15 16-Feb-15 14-Jan-15 11-Feb-15 21-Jan-15 22-Jan-15

PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells

Polio Bulletin

Table 2B. Laboratory investigation of AFP cases with onset in 2015 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with positive specimens L20B positive + NPEV NPEV only Pending ≤ 14 Negative days % % results Latest Pending reported specimens positive report date > 14 2 ≤ 14 days for NPEV days ≥ 80% Intratypic differentiation/ 1 Sequencing lab No. of isolates received Type 1 Wild Sabin VDPV W ild Intratypic differentiation (ITD)/sequencing results Type 2 Type 3 Sabin VDPV W ild Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%

1 1 4 629 27 7 20 5 41 28 37 11 67 30 38 15 9 12 53 6 23 60 13 10 19 36 9 15 5 12 12 6 2 1 0 3 0 0 4 16 2 0 2 141 12 2 17 10 0 844

0 0 0 8 0 0 0 0 1 0 0 0 2 0 1 2 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 15 0 0 2 0 18

1 1 4 576 25 7 20 5 40 28 37 11 65 29 34 10 9 1 52 6 23 46 12 8 16 32 8 14 5 12 12 6 2 1 3 4 15 2 1 117 8 2 14 9 757

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 4 0 1 1 15

0 0 0 45 2 0 0 0 0 0 0 0 0 1 3 3 0 11 1 0 0 14 0 2 3 3 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 46

0% 100% 100% 96% 92% 100% 95% 100% 100% 100% 100% 100% 93% 100% 93% 100% 100% 100% 100% 100% 82% 98% 100% 100% 100% 88% 100% 86% 100% 92% 100% 100% 100% 100% 82% 100% 100% 75% 100% 94% 100% 100% 100% 89% 96%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 3% 0% 0% 8% 0% 0% 10% 0% 0%

02-Mar-15 02-Mar-15 23-Feb-15 25-Mar-15

0 0 0 14 0 2 0 0 3 0 0 0 1 0 0 4 0 0 0 0 0 0 2 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14

0 0 0 0 0 0 0 0 0

6 0 2 1 2 0 1 0 6

0 0 0 0 0 0 0 0 0

4 2 0 0 2 0 0 0 4

1 0 1 0 0 0 0 0 1

0 0 0 0 0 0 0 0 0

3 0 0 0 0 2 0 1 3

0 0 0 0 0 0 0 0 0

79% 0% 100% 100% 100% 100% 100% 0% 79%

25-Mar-15 25-Mar-15 09-Mar-15 11-Mar-15 30-Mar-15 05-Mar-15 02-Mar-15 24-Mar-15 18-Mar-15 14-Feb-15 12-Mar-15 12-Mar-15 02-Mar-15

CCDC PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

Polio Bulletin

Table 3A. Laboratory confirmation of polio isolates from other sources in 2014 Non-AFP cases Country Intratypic differentiation lab 2 Total number Total number of non-AFP of non-AFP cases tested cases with for polio polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV Pending NPEV ITD Discordant Total number pending of samples sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 NPEV Sabin VDPV Pending ITD Discordant pending sequencing

96 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 203 0 0 3 0 0 0 0 0 305

0 3 1 2 0 3 6

0 0 0 0 0 0 0

0 3 1 2 0 1 4

0 0 0 0 0 0 0

0 0 0 0 0 1 1

0 0 0 0 0 0 0

0 1 0 1 0 1 2

0 0 0 0 0 0 0

0 0 0 0 23 0 23

0 0 0 0 0 0 0

3 0 0 167 0 0 14 0 48 0 0 18 0 0 0 0 0 0 48 12 0 0 0 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 191

0 167 14 48 18 48 12 27 7 174

0 0 0 0 0 0 0 0 0

79 1 21 11 13 6 27 1 80

0 0 0 0 0 0 0 0 0

129 4 22 37 16 12 38 1 130

2 0 0 1 0 0 1 0 2

0 0 0 0 0 0 0 0 0

115 0 15 47 23 10 20 5 120

0 0 0 0 0 0 0 0 0

3 0 0 0 0 0 0 0 7 10

0 0 0 0 0 0 0 0 0 0

1. Based on year of collection of sample, if available. Otherw ise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Polio Bulletin

Table 3B. Laboratory confirmation of polio isolates from other sources in 2015 Non-AFP cases Country Intratypic differentiation lab 2 Total number Total number of non-AFP of non-AFP cases tested cases with for polio polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV Pending NPEV ITD Discordant Total number pending of samples sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 NPEV Sabin VDPV Pending ITD Discordant pending sequencing

23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 26 0 0 2 0 0 0 0 0 51

0 0 2 2

0 0 0

0 1 1

0 0 0

0 1 1

0 0 0

0 2 0 2

0 0 0 0

8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8

1 1

0 0

1 1

0 0

5 5

0 0

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Polio Bulletin

Table 4. Vaccine-derived poliovirus, 2000–2015 Country Cambodia

2000–2009

2010

2011

2012

2013

2014

2015

2006 (1 case) Total (2 cases) 2009 (1 case) Total (27 cases) 2005 (3 cases) 2005 (1 case) Total (2 cases) 2004 (3 cases) 2003 (1 case) 2001 (3 cases) aVDPV2 (2 cases) ?VDPV2 (1 case) aVDPV2 (5 cases) aVDPV3 (2 cases) aVDPV1 (1 case) aVDPV2 (3 cases) cVDPV2 (2 cases) iVDPV2 (2 cases) iVDPV3 (1 case) aVDPV1 (1 case) aVDPV2 (2 cases) aVDPV2 (1 case) cVDPV2 (3 cases) iVDPV2 + iVDPV3 (1 case) iVDPV2 + iVDPV3 (1 case) aVDPV1 (1 case) aVDPV2 (2 cases) iVDPV3 (1 case)

China China, Hong Kong SAR Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam

?VDPV2 (1 case)

1. Prefix letter refers to the VDPV category - "cVDPV" = circulating VDPV, "iVDPV" = immunodeficiency-associated VDPV, "aVDPV" = ambiguous VDPV, "?VDPV" = unknown. Suffix number refers to the poliovirus serotype (types 1, 2 or 3). 2. Refers to year of last VDPV case, and aggregate total of VDPV cases for 2000-2009

Polio Bulletin

Key facts

Organisation World Health Organization (WHO)

Document type Technical Documents

Adoption date March 31, 2015

Source World Health Organization